Merck KGaA
Merck Invests $169M in Selective PARP1 Drug, Intensifying Competition with AstraZeneca and Gilead
Anika Sharma
Merck KGaA is making a strategic move in the field of PARP inhibitors, investing a substantial 160 million euros ($169 ...
Merck KGaA launches campaign to educate doctors on rare MS type, challenging Sanofi
Anika Sharma
Merck KGaA is gearing up for a significant milestone in the development of its multiple sclerosis (MS) drug candidate. As ...
Merck KGaA’s MilliporeSigma Invests €28 Million in 2 New mRNA Production Facilities
Anika Sharma
Merck KGaA’s MilliporeSigma has taken significant steps in its €1 billion initiative to establish a global mRNA network, enhancing its ...
Merck KGaA signs two deals with BenevolentAI and Exscientia to boost AI-driven drug discovery in oncology and immunology
Anika Sharma
Merck KGaA is making strategic moves in the field of AI-enabled drug discovery by entering into three-target partnerships with BenevolentAI ...
CDMO Experiences Downturn at Merck KGaA as COVID-Related Sales Plunge, Says CFO
SG Tylor
Merck KGaA is facing the challenges it anticipated for 2023, with its contract manufacturing division and process solutions arm experiencing ...
